Clinical Trial Detail

NCT ID NCT02583477
Title Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Indications

pancreatic ductal adenocarcinoma

Therapies

AZD5069 + Durvalumab

Durvalumab + Gemcitabine + Nab-paclitaxel

Age Groups: adult

No variant requirements are available.